Table 2: Brain and plasma kynurenine metabolite analysis
following chronic unpredictable stress.
|
|
0 days CUS |
10 days CUS |
20 days CUS |
30 days CUS |
Main effects |
|
Brain metabolites (μM) |
|||||
|
Tryptophan |
344.9 (49.50) |
692.2 (114.5) † |
630.9 (93.02) |
356.7 (42.87) |
*p<0.05 |
|
Kynurenine |
0.15 (0.027) |
0.41 (0.068) †††† |
0.33 (0.073) |
0.29 (0.098) |
n.s. |
|
3-HK |
0.036 (0.013) |
0.026 (0.0140) |
0.018 (0.0022) |
0.04 (0.018) |
n.s. |
|
XT |
0.023 (0.00097) |
0.004 (0.0011) †† |
0.013 (0.0027) |
0.022 (0.0057) |
**p<0.01 |
|
3-HAA |
0.02 (0.013) |
0.0038 (0.0038) |
0.0056 (0.0035) |
0.021 (0.0078) |
n.s. |
|
PA |
1.072 (0.11) |
2.55 (0.35) †† |
2.22 (0.36) † |
2.01 (0.77) |
n.s. |
|
QA |
n.d. |
n.d. |
n.d. |
n.d. |
n/a |
|
KYNA |
0.033 (0.0036) |
0.014 (0.0024) |
0.021 (0.0017) |
0.045 (0.013) |
*p<0.05 |
|
Plasma metabolites
(μM) |
|||||
|
Tryptophan |
955.3 (67.80) |
887.3 (38.68) |
1053 (66.07) |
966.7 (70.37) |
n.s. |
|
Kynurenine |
1.110 (0.08282) |
1.149 (0.07760) |
1.432 (0.1713) |
1.175 (0.1713) |
n.s. |
|
3-HK |
0.058 (0.029) |
0.057 (0.015) |
0.069 (0.02) |
0.052 (0.0094) |
n.s. |
|
XT |
0.053 (0.0015) |
0.048 (0.0049) |
0.051 (0.0035) |
0.054 (0.0034) |
n.s. |
|
3-HAA |
n.d. |
n.d. |
n.d. |
n.d. |
n/a |
|
PA |
1.47 (0.082) |
1.13 (0.087) |
1.31 (0.089) |
1.26 (0.1) |
n.s. |
|
QA |
0.39 (0.12) |
0.15 (0.021) † |
0.19 (0.018) † |
0.23 (0.026) |
*p<0.05 |
|
KYNA |
0.049 (0.0028) |
0.048 (0.0052) |
0.064 (0.007) |
0.056 (0.0049) |
n.s. |
3-HK: 3-Hydroxykynurenine; XT:
Xanthurenic Acid; 3-HAA: 3-Hydroxyanthranilic
Acid; PA: Picolinic Acid; QA: Quinolinic Acid; KYNA: Kynurenic Acid.
Kynurenine
pathway metabolites were quantified (μM) by LC/MS in the whole brain and plasma
samples from male C67Bl/6J mice following 0, 10, 20, or 30 days of chronic unpredictable
stress. Concentration values represent sample means (s.e.m.) n = 4-6 samples
per group.
*:
Main effect of CUS, p < 0.05.
†:
Post hoc comparison with 0 days CUS control group.
*,†:
p<0.05; **,††: p<0.01.